| Range | 50.00 - 51.22 |
| 52 week | 40.76 - 65.60 |
| Open | 50.25 |
| Vol / Avg. | 2.77M/2.40M |
| Mkt cap | 19.78B |
| P/E | 23.86 |
| Div/yield | 0.52/1.03 |
| EPS | 2.13 |
| Shares | 388.73M |
| Beta | 1.29 |
| Inst. own | 59% |
| Q1 (Mar '12) | 2011 | |
| Net profit margin | 5.84% | 7.99% |
| Operating margin | 9.41% | 12.37% |
| EBITD margin | - | 15.75% |
| Return on average assets | 8.14% | 12.12% |
| Return on average equity | 19.15% | 30.62% |
| Employees | 32,300 | - |
| Carbon Disclosure Rating | - | 77/100 |
| William P. Lauder | Executive Chairman of the Board | |
| Fabrizio Freda | President, Chief Executive Officer, Director | |
| John D. Demsey | Group President | |
| Richard W. Kunes | Chief Financial Officer, Executive Vice President | |
| Ronald S. Lauder | Chairman of Clinique Laboratories, LLC. | |
| Cedric Prouve | Group President - International | |
| Sara E. Moss | Executive Vice President, General Counsel | |
| Amy DiGeso | Executive Vice President - Global Human Resources | |
| Carl Haney | Executive Vice President - Global R&D, Corporate Product Innovation, Package Development | |
| Gregory F. Polcer | Executive Vice President - Global Supply Chain |